Eli Lilly in 2Q17: Performance of Cardiovascular Products
Eli Lilly and Company’s (LLY) cardiovascular franchise contributes nearly 15.0% to the company’s total revenues. Key drugs in this segment are Cialis and Effient.
Interested in LLY? Don't miss the next report.
Receive e-mail alerts for new research on LLY
Cialis, a drug for the treatment of erectile dysfunction and benign prostatic hyperplasia, is a blockbuster drug in Eli Lilly’s cardiovascular portfolio. Cialis reported nearly flat revenues of $627.3 million in 2Q17 compared to $630.5 million in 2Q16. That included a 1.0% fall in US revenues and nearly flat international revenues. US sales fell due to competition, while international markets reported lower sales and the negative impact of foreign exchange, offset by higher realized prices.
Effient is an antiplatelet drug used in combination with aspirin for the prevention of blood clots in arteries and stents, thus reducing the chances of heart-related events for patients with acute coronary syndrome. Effient reported a rise of 6.0% in revenues to $142.9 million in 2Q17 compared to $135.1 million in 2Q16.
Other cardiovascular drugs
In addition to Cialis and Effient, Eli Lilly has two more cardiovascular drugs in its product portfolio: Adcirca and Reopro. Adcirca reported revenues of $22.8 million for 2Q17, while Reopro reported revenues of $2.6 million.
To divest the company-specific risks, you can consider the iShares US Healthcare (IYH), which holds 2.6% of its assets in Eli Lilly. IYH also holds 6.8% of its total assets in Pfizer (PFE), 3.4% in AbbVie (ABBV), and 6.2% in Merck & Co. (MRK).